Taiwanese (TAIEX) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE
Wed, 26 Jan 2022	NT$1.1t	NT$202.1b	NT$14.1b	21.5x
Fri, 24 Dec 2021	NT$1.2t	NT$202.1b	NT$14.1b	21.9x
Sun, 21 Nov 2021	NT$1.1t	NT$202.4b	NT$13.3b	20.4x
Tue, 19 Oct 2021	NT$1.0t	NT$197.1b	NT$14.2b	20.5x
Thu, 16 Sep 2021	NT$1.0t	NT$197.1b	NT$14.2b	21.5x
Sat, 14 Aug 2021	NT$1.1t	NT$197.0b	NT$14.1b	22x
Wed, 09 Jun 2021	NT$1.1t	NT$191.4b	NT$14.8b	20.9x
Tue, 02 Mar 2021	NT$940.9b	NT$186.1b	NT$9.7b	19.1x
Fri, 04 Dec 2020	NT$923.3b	NT$179.1b	NT$4.8b	20.9x
Mon, 07 Sep 2020	NT$955.7b	NT$174.2b	NT$2.1b	22.7x
Sun, 31 May 2020	NT$789.5b	NT$171.3b	-NT$2,449,886,500.00	23.4x
Wed, 04 Mar 2020	NT$637.6b	NT$170.7b	-NT$2,703,537,000.00	21x
Sat, 07 Dec 2019	NT$664.2b	NT$167.5b	NT$1.6b	19.6x
Tue, 10 Sep 2019	NT$637.2b	NT$169.8b	NT$3.1b	19.6x
Mon, 03 Jun 2019	NT$638.8b	NT$173.0b	NT$3.9b	20.8x
Thu, 07 Mar 2019	NT$673.9b	NT$174.5b	NT$5.3b	21.5x


Biotech	0.076%
Healthcare Services	-1.58%
Healthtech	-1.64%
Pharma	-2.15%
Medical Equipment	-2.99%
Life Sciences	-3.80%

Company	Last Price	7D	1Y	Valuation
6446 PharmaEssentia	NT$289.00	16.5% +NT$11.2b	216.9%	PS138.8x
6586 CHO Pharma	NT$123.00	35.6% +NT$5.9b	400.0%	PB12.2x
4174 OBI Pharma	NT$118.50	8.7% +NT$1.9b	0.9%	PS249x
6562 UBI Pharma	NT$72.90	8.6% +NT$611.0m	n/a	PS14.1x
6696 Lin BioScience	NT$213.00	4.2% +NT$586.4m	100.9%	PB25.6x

Jan 25

OBI Pharma, Inc. Announces Phase 2 Studies Patient Enrollment for Obi-999 and Obi-3424

OBI Pharma, a Taiwan biopharma company announced that the first patients have been enrolled in both of the Phase 2 studies of OBI-999, an antibody drug conjugate (ADC) cancer therapy targeting Globo H, and OBI-3424, a prodrug targeting the enzyme aldo-keto reductase 1C3 (AKR1C3). The Phase 2 cohort expansion part of the OBI-999-001 (ClinicalTrials.gov Identifier: NCT04084366) entitled "A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors" has now begun enrollment. The Phase 2 part of the study will enroll Globo H expressing patients with pancreatic, colorectal and other high Globo H expression solid tumors in more than ten medical centers in the United States and Taiwan. The Phase 2 cohort expansion part of the OBI-3424-001 (ClinicalTrials.gov Identifier: NCT03592264) entitled "A Phase 1/2 Study of OBI-3424 in Subjects with Advanced Solid Tumors" has also begun enrollment. This study will enroll AKR1C3 expressing patients with pancreatic and other high AKR1C3 expressing solid tumors in select oncology medical centers in the United States. OBI anticipates completing the enrollment of both Phase 2 studies in the second half of 2023. OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment that is based on Globo H, an antigen expressed in up to 15 epithelial cancers. OBI-999 uses a Globo H antibody to target cancer cells of high Globo H expression. By releasing a small molecule chemotherapeutic drug through the specificity of the antibody, it directly deploys cytotoxic therapy at the targeted cancer cells. In pre-clinical xenograft animal models in multiple tumor types (gastric, pancreatic, lung and breast), OBI-999 has demonstrated profound tumor shrinkage at various doses. In human Phase 1 study, OBI-999 was well-tolerated, and achieved a favorable safety margin which warrants further clinical development. OBI-999 is currently in a Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) in medical centers in the US and Taiwan. OBI Pharma owns global rights to OBI-999. OBI-3424 is a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1C3 (AKR1C3), and selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme. This selective mode of activation distinguishes OBI-3424 from traditional alkylating agents, such as cyclophosphamide and ifosfamide, which are non-selective. AKR1C3 overexpression has been documented in a number of treatment-resistant and difficult-to-treat cancers including hepatocellular carcinomas (HCC), castrate-resistant prostate cancer (CRPC), and T-cell acute lymphoblastic leukemia (T-ALL). AKR1C3 is highly expressed in up to 15 solid and liquid tumors. Furthermore, individualized patient selection by staining for AKR1C3 overexpression by immunohistochemistry can be performed based on tumor biopsies or circulating tumor cells to identify patients with other tumor types most likely to respond to treatment with OBI-3424, and thus offering the possibility for a streamlined clinical development strategy. OBI-3424 is currently in a Phase 2 trial (ClinicalTrials.gov Identifier: NCT03592264) in medical centers in the US. OBI owns global rights to OBI-3424 except the Asia Pacific region.

Jan 09

Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

Golden Biotechnology Corporation announced that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure in hospitalized mild, moderate including ICU severe patients. In line with the plan, GoldenBiotech will submit the final clinical trial analysis report and related R&D documents to the US FDA to apply for emergency use authorization (EUA) for Antroquinonol (HOCENA®). This trial is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Antroquinonol in hospitalized patients with mild to moderate pneumonia due to COVID-19 (Coronavirus SARS-CoV-2 disease). Actually, the trial also included the ICU severe patients who need oxygen support. Following completion of all screening assessments and meeting of eligibility criteria, patients will either receive 100mg of Antroquinonol or placebo two times a day for 14 days in combination with Standard of Care (SoC) therapy per local SoC policies. The trial completed recruiting for 124 patients in the USA, Peru and Argentina where the new pandemic upheaval is rampant with highly transmitted SARS-CoV-2 variants. The clinical trial data revealed: Primary Outcome Measure: recover ratio [Time Frame: 14 days]. The proportion of patients who are alive and free of respiratory failure (e.g., no need for invasive mechanical ventilation, non-invasive ventilation, high flow oxygen, or ECMO) on Day 14. Result: In the Antroquinonol group, the recovery ratio was 97.9% at the day 14 visit. Furthermore, no death or respiratory failure was found in the Antroquinonol group at the day 28 visit with recovery ratio of 100%. Secondary Outcome Measures: (a) Duration of ICU Stay: Result: The median duration of ICU stay in Antroquinonol group was 9.5 days shorter than that in the placebo group. (b) Duration of hospitalization [Time Frame: 28 days]: time for patient discharge. Result: The median duration of hospitalization was 4 days in the Antroquinonol group. (c) Time to 2-point improvement [Time Frame: 28 days]: Clinical change score as measured by the "WHO COVID-19 Clinical Improvement Ordinal Scale". Result: The median time to score of 0 in "WHO COVID-19 Clinical Improvement Ordinal Scale" was 29 days in the antroquinonol group. (d) Time to virological clearance [ Time Frame: 28 days]: measured as study days from start of treatment to first negative SARS-CoV-2 PCR test. Result: The median time to virological clearance was 14 days in the Antroquinonol group. In safety evaluation, the data revealed that Antroquinonol showed good tolerability and safety results.

Taiwanese (TAIEX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

4171

Investor sentiment deteriorated over the past week

4174

OBI Pharma, Inc. Announces Phase 2 Studies Patient Enrollment for Obi-999 and Obi-3424

4132

Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

6491

Price target decreased to NT$592

4743

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

8406

Investor sentiment improved over the past week

6541

Price target decreased to NT$53.00

6446

Third quarter 2021 earnings released: NT$2.70 loss per share (vs NT$2.42 loss in 3Q 2020)

6589

Third quarter 2021 earnings released: EPS NT$1.36 (vs NT$0.34 loss in 3Q 2020)

6547

Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020)

4142

Third quarter 2021 earnings released: EPS NT$0.37 (vs NT$0.38 in 3Q 2020)

1760

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

6562

First half 2021 earnings released: NT$0.43 loss per share (vs NT$1.05 loss in 1H 2020)

6586

Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)

6696

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

6580

Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth